Other substances

Thymosin α1

An immunomodulatory peptide.

Phase of research

Potential treatment - clinical evidence

How it helps

Antiviral

Drug status

Experimental

Supporting references

Contradictory references

AI-suggested references

Clinical trials

General information

Thymosin α1 is an immunomodulatory peptide with possible use for the treatment of sepsis, in chemotherapy-induced immunosuppression, acquired immune deficiency syndrome and other (Wu et al., 2020).

Thymosin α1 on Wikipedia

Supporting references

Link	Tested on	Impact factor	Notes	Publication date
Thymosin α1 therapy in critically ill patients with COVID-19: A multicenter retrospective cohort study Peptide Critical severity Cohort study	Patients	3.94	The treatment significantly decreased 28-day mortality and attenuated acute lung injury in critically ill COVID-19 patients. It prolonged the hospital length of stay and the total duration of the disease, however. Sample size: 102 + 232 control. Dosage: 1.6 mg qd or q12 h for >5 days. Endpoints: 28-day and 60-day mortality (primary); hospital length of stay and the total duration of the disease (secondary).	Aug/06/2020

AI-suggested references

Link	Publication date
Thymosin alpha1 therapy in critically ill patients with COVID-19: A multicenter retrospective cohort study.	Aug/06/2020
The effect of thymosin alpha1 on mortality of critical COVID-19 patients: A multicenter retrospective study.	Oct/31/2020
PASylated Thymosin alpha1: A Long-Acting Immunostimulatory Peptide for Applications in Oncology and Virology	May/21/2020
Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells: A case report.	Jul/31/2020

Export (.csv)